Highest-materiality recent filing
Inhibitor Therapeutics sues investor for failing to close $3M financing
Filed suit March 30, 2026 against an institutional investor for breach of the Securities Purchase Agreement.
Inhibitor Therapeutics enters $3M private placement; sells 12M shares and warrants
Company to sell 12,000,000 shares of common stock at $0.25/share to an institutional investor, raising $3M.
Inhibitor Therapeutics signs exclusive worldwide license with JHU for itraconazole in three cancers
Exclusive worldwide license to U.S. Patent 8,980,930 covering itraconazole as an angiogenesis inhibitor.
Inhibitor Therapeutics appoints Michelle Yanez as director, forms Scientific Advisory Board
Michelle Yanez appointed as independent director and Audit Committee member, effective Oct 13, 2023.
Inhibitor Therapeutics settles derivative and class actions, appoints new CEO and board
Settlement provides $14.25M cash payment to company from Mayne Pharma's D&O insurance.
Mayne to pay $14.25M cash and surrender all its equity (205M+ common shares, convertible preferred, warrants); Mayne debt of $3M canceled.
On October 13, 2023, the Board of Directors (the “ Board ”) of Inhibitor Therapeutics, Inc. (the “ Company ”) appointed Michelle Yanez to fill one of the vacancies of the Board.
On August 23, 2023, the Board of Directors (the “ Board ”) of Inhibitor Therapeutics, Inc. (the “ Company ”) increased the number of directors on the Board from four (4) members to seven (7) members and appointed Ronald E. Osman to fill one of the vacancies of the Board.
On May 24, 2023, the Board of the Company appointed Michael Jerman, CPA. as an independent member of its Board.
On and effective May 24, 2023, Michelle Yanez gave notice to Inhibitor Therapeutics, Inc. (the “Company”) of her resignation from the Board of Directors of the Company (the “Board”).
On December 10, 2022, and in furtherance of the transactions contemplated by the Settlement Agreement, W. Mark Watson, Stefan J. Cross, Dr. R. Dana Ono, and Robert D. Martin (collectively, the “Resigning Directors”) gave notice of the Company of their resignation from the Board to be effective on December 13, 2022.
On December 10, 2022, and in furtherance of the transactions contemplated by the Settlement Agreement, W. Mark Watson, Stefan J. Cross, Dr. R. Dana Ono, and Robert D. Martin (collectively, the “Resigning Directors”) gave notice of the Company of their resignation from the Board to be effective on December 13, 2022.
On December 10, 2022, and in furtherance of the transactions contemplated by the Settlement Agreement, Nicholas J. Virca and Garrison J. Hasara (collectively, the “Resigning Officers”) gave notice of the Company of their resignation from their officer positions to be effective on December 13, 2022.
On December 13, 2022, the Board of the Company appointed Francis E. O’Donnell, Jr., M.D. as Executive Chairman of its Board and as Chief Executive Officer of the Company.
On December 10, 2022, and in furtherance of the transactions contemplated by the Settlement Agreement, Nicholas J. Virca and Garrison J. Hasara (collectively, the “Resigning Officers”) gave notice of the Company of their resignation from their officer positions to be effective on December 13, 2022.
On December 10, 2022, and in furtherance of the transactions contemplated by the Settlement Agreement, W. Mark Watson, Stefan J. Cross, Dr. R. Dana Ono, and Robert D. Martin (collectively, the “Resigning Directors”) gave notice of the Company of their resignation from the Board to be effective on December 13, 2022.
On December 13, 2022, the Board of the Company appointed Francis E. O’Donnell, Jr., M.D. as Executive Chairman of its Board and as Chief Executive Officer of the Company.
On December 10, 2022, and in furtherance of the transactions contemplated by the Settlement Agreement, W. Mark Watson, Stefan J. Cross, Dr. R. Dana Ono, and Robert D. Martin (collectively, the “Resigning Directors”) gave notice of the Company of their resignation from the Board to be effective on December 13, 2022.
Max materiality 0.90 · Median 0.55 · Most common event other_material